Combination of hypertension and hypercholesterolemia

Video presentation

Click to watch the video

Combination of hypertension and hypercholesterolemia

E-learning Modules

Launch: 30 April 2024


The combination of arterial hypertension and hypercholesterolemia poses a significant threat to public health, as both are modifiable risk factors for cardiovascular disease (Tadic and Cuspidi, 2019).  A correlation exists between hypertension and hypercholesterolemia, with their combination significantly elevating the risk of cardiovascular events, such as myocardial infarction and stroke (Tadic and Cuspidi, 2019); (Borghi, Urso, and Cicero, 2017). Therefore, early detection and treatment of both risk factors are essential for enhancing a patient’s health profile, particularly when integrating antihypertensive and cholesterol-lowering medications (Tadic and Cuspidi, 2019); (Borghi, Urso, and Cicero, 2017). In addition to medications, addressing modifiable risk factors through patient education and lifestyle interventions is critical in improving control rates, as poor control of hypertension and hypercholesterolemia correlates with obesity, smoking, and low physical activity (Mach, 2020). However, despite the availability of effective medications and an understanding of the link between hypertension and hypercholesterolemia, the control of the combination of these conditions remains low (Tadic and Cuspidi, 2019). Several reasons contribute to this issue, including inadequate disease screening, insufficient assessment and management of modifiable risk factors, and poor treatment adherence (Mach, 2020). Therefore, healthcare professionals need to be trained to adopt a comprehensive approach to early diagnosis and management of hypertension and hypercholesterolemia. This approach should include treatment adherence and lifestyle modifications, as well as utilizing telemedicine as a viable, effective alternative to in-person visits to ensure timely screening and early diagnosis of hypertension, dyslipidemia, and diabetes (Mabeza, Maynard, and Tarn, 2022). This video presentation will focus on modifiable risk factors for hypertension and hypercholesterolemia and the use of telemedicine support as part of the early diagnosis and management for patients at risk. 

Learning Objectives

At the end of the video presentation, participants will be able to:

Target Audience

Clinicians (including cardiologists, internists, and general practitioners), nurse practitioners and other HCPs who manage patients with hypertension and heart failure.


English with voice-over into Russian and Chinese


Harry A.J. Struijker-Boudier

Harry A.J. Struijker-Boudier

Emeritus Professor of Pharmacology
Maastricht University
The Netherlands

Save the Date

Download Save the Date

· Harry A. J. Struijker-Boudier ·

Harry Struijker-Boudier is emeritus professor of pharmacology at Maastricht University in the Netherlands and former director of the Cardiovascular Research Institute Maastricht. His scientific career focused on cardiovascular pharmacology and pharmacotherapy, in particular in the area of hypertension. He was member and vice-chairman of the Scientific Council of the European Society of Hypertension as well as board member of the European Federation of Pharmacological Societies and the council member of the International Society of Vascular Health. In addition to his position at Maastricht University he held appointments as visiting professor at several universities in the United States, Asia and Europe. At present he is chairman of the Scientific Board of the Paris Cardiovascular Research Center and the Nancy Cardiovascular Research Center in France. He (co)authored more than 500 papers in international journals and books on cardiovascular diseases and their treatment. The total number of citations of these papers is >40,000. He is doctor honoris causa of the Université de Liège in Belgium, recipient of the Descartes-Huygens prize of the French Government and Officer of the Order of Oranje-Nassau of the Dutch Royal House.

· Martin O. Savage ·

Martin Savage is Emeritus Professor of Paediatric Endocrinology at William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Queen Mary, University of London. He was head of the Paediatric Endocrine Unit at Barts and the London School of Medicine from 1982 to 2007. He has interests in growth disorders, specifically those with abnormalities in the GH-IGF-1 axis and in phenotype-genotype relationships of GH-IGF-1 axis defects, notably GH resistance. He published the first human case of an IGF-1 gene defect in the New England Journal of Medicine in 1996.  His other interests are Cushing’s syndrome and growth in chronic inflammatory diseases. He was General Secretary of the European Society for Paediatric Endocrinology (ESPE) from 1997 to 2004. He has lectured in 60 countries and has published 482 original articles, reviews, textbook chapters and books. In 2007, he was awarded the ESPE Andrea Prader Prize for contributions to paediatric endocrinology and in 2018 he received a Visionary Award from the American Human Growth Foundation. In 2022, he received a Research Excellence Award from the Dr Sulaiman Al Habib Medical Journal in Riyadh, and the British Society of Paediatric Endocrinology & Diabetes James M. Tanner Lifetime Achievement Award. He continues to lecture nationally and internationally.